The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a MDM2 inhibitor.La presente invención es concerniente con la terapia combinada de un anticuerpo anti-CD20 afucosilado con un inhibidor de MDM2 para el tratamiento de cáncer, especialmente con la terapia combinada de canceres que expresan CD20 con un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de MDM2.
